Is eLMO3 a novel biomarker for diagnosis and prognosis of non-small cell lung cancer?
The over-expression of ELMO3 was a potential diagnostic and prognostic marker for NSCLC.
Relapse after curative surgery because of local recurrence or regional lymph node metastasis have been shown in up to 87.5% of patients. The extent of surgery, however, may be of influence on the locoregional recurrence rate.